Bharat Biotech, on July 20, announced that the third dose of COVID-19 vaccine Covaxin has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials.
The study, which was conducted on about 184 subjects, who were randomised 1:1 and received either a booster dose of BBV154 or a placebo, nearly six months after the primary series of 2 doses, has been published in Nature.
Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike protein, receptor binding domain, N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity.
Krishna Ella, chairman and managing director, Bharat Biotech, said, “Our team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD, and N proteins.”
Post-booster dose, according to Ella, the vaccine has proven neutralising antibody responses against variants of concern and long-term protection through memory T and B cell responses.
“We have now achieved our goal of developing a safe and efficacious vaccine with long-term protection against a spectrum of variants.”
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
